Laboratorios Rubió, a family company specialising in treatment solutions for low prevalence diseases, has acquired 30% of the company Biosfer Teslab, a spin-off of the Universidad Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), to drive the development of a predictive test for cardiovascular risk that is the first of its kind in Europe.
As part of its commitment in the field of R&D&i, Rubió will make an initial investment of more than half a million Euros to undertake the final phase of product development and its launch onto the market. The company will hold exclusive rights in the European market, and have preferential rights over the product in the rest of the world. The new product, which will be available on the market in 2016, is an advanced lipoprotein test that allows the size and concentration of particles that transport LDL to be calculated, since these characteristics make it possible to more accurately assess the risk of suffering from cardiovascular problems.
